Shell Asset Management CO Fate Therapeutics Inc Transaction History

Shell Asset Management CO

  • $2.27 Billion
  • Q3 2024

A detailed history of Shell Asset Management CO transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Shell Asset Management CO holds 1 shares of FATE stock, worth $2. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$2
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$3.54 - $8.35 $209,925 - $495,163
-59,301 Reduced 100.0%
1 $0
Q4 2023

Feb 14, 2024
SELL
$1.65 - $3.94 $29,530 - $70,514
-17,897 Reduced 23.18%
59,302 $222,000
Q3 2023

Nov 08, 2023
BUY
$2.02 - $5.04 $148,381 - $370,218
73,456 Added 1962.49%
77,199 $164,000
Q2 2023

Jul 28, 2023
SELL
$4.76 - $6.59 $99 - $138
-21 Reduced 0.56%
3,743 $18,000
Q1 2023

May 15, 2023
SELL
$4.24 - $11.12 $55 - $144
-13 Reduced 0.34%
3,764 $21,000
Q4 2022

Feb 07, 2023
SELL
$9.86 - $23.83 $7,542 - $18,229
-765 Reduced 16.84%
3,777 $38,000
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $25,037 - $42,911
-1,190 Reduced 20.76%
4,542 $102,000
Q2 2022

Aug 09, 2022
BUY
$17.78 - $42.39 $160 - $381
9 Added 0.16%
5,732 $142,000
Q1 2022

May 04, 2022
SELL
$29.67 - $60.28 $25,160 - $51,117
-848 Reduced 12.91%
5,723 $222,000
Q4 2021

Feb 09, 2022
BUY
$47.84 - $64.34 $1,722 - $2,316
36 Added 0.55%
6,571 $384,000
Q3 2021

Nov 04, 2021
SELL
$59.27 - $95.73 $17,188 - $27,761
-290 Reduced 4.25%
6,535 $387,000
Q2 2021

Aug 12, 2021
BUY
$67.25 - $92.52 $458,981 - $631,449
6,825 New
6,825 $592,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email